You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
L-type Ca2+ channel blocker that displays higher vascular selectivity than felodipine (Cat. No. 2960). Causes peripheral vasodilation with only weak negative inotropic activity. Antihypertensive. Also exhibits anti-MERS-CoV activity in Vero cells in vitro (IC50 = 2.36 μM).
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 648.19. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.54 mL||7.71 mL||15.43 mL|
|5 mM||0.31 mL||1.54 mL||3.09 mL|
|10 mM||0.15 mL||0.77 mL||1.54 mL|
|50 mM||0.03 mL||0.15 mL||0.31 mL|
References are publications that support the biological activity of the product.
Bang et al (2003) Lercanidipine. A review of its efficacy in the management of hypertension. Drugs 63 2449 PMID: 14609358
Wirtz and Herzig (2004) Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine. Br.J.Pharmacol. 142 275 PMID: 15155536
Sironi et al (1996) Antihypertensive effects of lercanidipine in experimental hypertensive rats and dogs. Arzneim.Forsch. 46 152
Ko et al (2020) Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19. BioRxiv - Paper not yet peer reviewed
If you know of a relevant reference for Lercanidipine hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Lercanidipine hydrochloride, Lercanidipine hydrochloride supplier, Ca2+, channel, blockers, L-type, Calcium, CaV, Channels, L-Type, voltage-gated, voltage-dependent, COVID-19, MERS-CoV, middle, eastern, respiratory, syndrome, Cav1.x, Coronavirus, 2959, Tocris Bioscience
1 Citation for Lercanidipine hydrochloride
Citations are publications that use Tocris products. Selected citations for Lercanidipine hydrochloride include:
Vasigar (2013) Anti-inflammatoryactivity of calciumchannel blocker lercanidipine hydrochloride. J Pharmacol Pharmacother 4 238 PMID: 24250199
Do you know of a great paper that uses Lercanidipine hydrochloride from Tocris? Please let us know.
Reviews for Lercanidipine hydrochloride
Average Rating: 5 (Based on 1 Review.)
Have you used Lercanidipine hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.